Participant flow

Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia · Source last updated 2016-04-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   A cycle of therapy consisted of bortezomib 1.3 mg/m(2) intravenously; dexamethasone 40 mg on days 1, 4, 8, and 11; and rituximab 375 mg/m(2) on day 11. Patients received four consecutive cycles for induction therapy and then four more cycles, each given 3 months apart, for maintenance therapy.

   id

   FG000

   title

   Bortezomib, Dexamethasone, Rituximab

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         23

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         23

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

Symptomatic patients with Waldenstrom's requiring therapy, previously untreated.

recruitment Details

Outpatient clinic at DFCI

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice